anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a UV-blocking cosmetic composition produced by being impregnated in foaming nitrile butadiene rubber (NBR) foam. Specifically, a water-in-oil-type (W/O) low viscosity UV-blocking composition is packed in a compact-type container, and a low viscosity W/O UV-blocking cosmetic composition is impregnated in foaming NBR foam and packed in a compact-type container, so user portability and usage convenience are improved and a cooling effect is also ensured. According to the present invention, a compact formulation UV-blocking cosmetic composition is produced by impregnating a UV-blocking composition in foaming NBR foam. The foaming NBR foam has a hardness of 15 to 35 on the basis of ASKER durometer Type F and a density of 180 to 240 g/L before contents are impregnated. A viscosity of the UV-blocking composition is 5000 to 15000 cps. Also, according to the present invention, a cosmetic container in which foaming NBR foam having a cosmetic composition impregnated therein is formed is produced, wherein the cosmetic composition contains a UV-blocking agent.
OBJECTIVE: To use intracranial electroencephalography (EEG) to characterize functional magnetic resonance imaging (fMRI) activation maps associated with high-frequency oscillations (HFOs) (80-250 Hz) and examine their proximity to HFO- and seizure-generating tissue.
METHODS: Forty-five patients implanted with intracranial depth electrodes underwent a simultaneous EEG-fMRI study at 3 T. HFOs were detected algorithmically from cleaned EEG and visually confirmed by an experienced electroencephalographer. HFOs that co-occurred with interictal epileptiform discharges (IEDs) were subsequently identified. fMRI activation maps associated with HFOs were generated that occurred either independently of IEDs or within ±200 ms of an IED. For all significant analyses, the Maximum, Second Maximum, and Closest activation clusters were identified, and distances were measured to both the electrodes where the HFOs were observed and the electrodes involved in seizure onset.
RESULTS: We identified 108 distinct groups of HFOs from 45 patients. We found that HFOs with IEDs produced fMRI clusters that were closer to the local field potentials of the corresponding HFOs observed within the EEG than HFOs without IEDs. In addition to the fMRI clusters being closer to the location of the EEG correlate, HFOs with IEDs generated Maximum clusters with greater z-scores and larger volumes than HFOs without IEDs. We also observed that HFOs with IEDs resulted in more discrete activation maps.
SIGNIFICANCE: Intracranial EEG-fMRI can be used to probe the hemodynamic response to HFOs. The hemodynamic response associated with HFOs that co-occur with IEDs better identifies known epileptic tissue than HFOs that occur independently.
BACKGROUND: The role of minimally invasive surgery (MIS) in the acute management of diverticulitis remains controversial. Using a national cohort, we examined the relationship between operative approaches with acute clinical and financial outcomes.
METHODS: Adults undergoing emergent colectomy for diverticulitis were tabulated from the 2015-2020 American College of Surgeons National Surgical Quality Improvement Program. Regression models were developed to analyze the association between open and MIS approaches with major adverse events (MAE), as well as secondary endpoints. A subgroup analysis was conducted to compare outcomes between open and MIS requiring conversion to open (CTO).
RESULTS: Of 9194 patients, 1580 (17.3%) underwent MIS colectomy. The proportion of MIS resection increased from 15.1% in 2015 to 19.1% in 2020 (nptrend<.001). Compared to Open, MIS patients were younger, equally likely to be female, had a lower proportion of patients with ASA class ≥3, and a higher BMI. Preoperatively, MIS patients were less frequently diagnosed with sepsis. Following adjustment with open as reference, MIS approach had reduced odds of MAE (AOR .56), ostomy creation (AOR .12), shorter postoperative length of stay (LOS; β -1.63), and a lower likelihood of nonhome discharge (AOR .45, all P < .001). Additionally, CTO was linked to decreased likelihood of MAE (AOR .78, P = .01), ostomy creation (AOR .02, P < .001), comparable LOS (β -.46, P = .41), and reduced odds of nonhome discharge (AOR .58, P < .001), relative to open.
DISCUSSION: Compared to planned open colectomy, MIS resection was associated with improved clinical and financial outcomes, even in cases of CTO. Our findings suggest that whenever possible, MIS should be attempted first in emergent colectomy for diverticulitis. Nevertheless, future prospective studies are likely needed to further elucidate specific patient and clinical factors.
Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications \[OAM(s)\] whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks.
The present invention provides new and advantageous methods, compositions, cell constructs and animal models related to inhibiting the senescence of vertebrate cells and vertebrate organisms based on the use of SIRT1 polynucleotides and polypeptides, as well as mutant SIRT1 polynucleotides and polypeptides. The invention provides polynucleotides that encode variants and fragments of SIRT1 polypeptides, and also provides variant SIRT1 polypeptides and fragments thereof. Additionally the invention provides a method of inhibiting or delaying the expression in a vertebrate cell of a protein having biological activity associated with loss of population doubling in the cell. The invention further provides a method of treating a pathology, a disease or a medical condition in a subject, wherein the pathology responds to an SIRT1 polypeptide. The invention also provides a vertebrate cell that incorporates a heterologous nucleic acid encoding a variant of SIRT1, or a fragment thereof, as well as a transgenic mammal a majority of whose cells harbor a transgene including a nucleic acid sequence encoding an SIRT1 polypeptide. The invention also provides an antibody that binds immunospecifically to a variant SIRT1 polypeptide or a fragment thereof, and a method of determining whether the amount of an SIRT1 polypeptide in a sample differs from the amount of the SIRT1 polypeptide in a reference. The invention further provides a method of contributing to the diagnosis or prognosis of, or to developing a therapeutic strategy for, a disease or pathology in a subject, wherein the disease or pathology responds to treatment with an SIRT1 polypeptide and wherein the amount of SIRT1 polypeptide in the pathology is known to differ from the amount of the SIRT1 polypeptide in a nonpathological state.
Systems, methods and computer program products for classifying documents are presented. Systems, methods and computer program products for analyzing documents, e.g. for verifying an association of an invoice with an entity are also presented. Systems, methods and computer program products for managing medical records are presented. One exemplary system includes a memory; and a processor in communication with the memory, the processor being configured to process at least some instructions stored in the memory. The memory stores computer executable program code comprising instructions for: training a classifier based on an invoice format associated with a first entity; accessing a plurality of invoices labeled as being associated with at least one of the first entity and other entities; and outputting an identifier of at least one of the invoices having a high probability of not being associated with the first entity.
Placebo is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include two patients.
The effects of dutasteride 0.5 mg/day on semen characteristics were evaluated in normal volunteers aged 18 to 52 (n = 27 dutasteride, n = 23 placebo) throughout 52 weeks of treatment and 24 weeks of post-treatment follow-up. At 52 weeks, the mean percent reductions from baseline in total sperm count, semen volume, and sperm motility were 23%, 26%, and 18%, respectively, in the dutasteride group when adjusted for changes from baseline in the placebo group. Sperm concentration and sperm morphology were unaffected. After 24 weeks of follow-up, the mean percent change in total sperm count in the dutasteride group remained 23% lower than baseline. While mean values for all semen parameters at all time-points remained within the normal ranges and did not meet predefined criteria for a clinically significant change (30%), 2 subjects in the dutasteride group had decreases in sperm count of greater than 90% from baseline at 52 weeks, with partial recovery at the 24-week follow-up. The clinical significance of dutasteride’s effect on semen characteristics for an individual patient’s fertility is not known.
Provided is a powdered solid cosmetic that lasts well and is excellent at preventing makeup running and oily shininess. Said powdered solid cosmetic is characterized by containing: a powder component; an oil-based component that serves as a binder; and a mixture of hexamethylenediamine and bis(aminomethyl)cyclohexane which has been amidated in hydrogenated castor oil fatty acid, resulting in an amide mixture. The amide mixture preferably constitutes 1.0–15% by mass of the cosmetic. As a powder component, spherical poly(metha)acrylate particles are preferably included, constituting 1–20% by mass of the cosmetic. An organically-denatured clay mineral is preferably included such that the mass thereof and the mass of the amide mixture total 1.0–15% of the total mass of the cosmetic. As a powder component, a powder treated by a fluorine compound is preferably included, constituting 5–97% by mass of the cosmetic.
BACKGROUND: Sarcopenia is a senile syndrome of age-related muscle loss. It is thought to affect the development of chronic kidney disease and has a serious impact on the quality of life of the elder adults. Little is known about the association between sarcopenia and new-onset chronic kidney disease in middle-aged and elder adults. Using nationally representative data from the China Health and Retirement Longitudinal Study (CHARLS), we conducted a longitudinal analysis to investigate the association between sarcopenia status and new-onset chronic kidney disease in middle-aged and elder adults in China.
METHODS: The study population consisted of 3676 participants aged 45 or older selected from 2011 CHARLS database who had no history of chronic kidney disease at the baseline and completed the follow-up in 2015. A multivariate cox regression model was employed to examine the association between sarcopenia and the incidence of new-onset chronic kidney disease.
RESULTS: Followed up for 4 years, a total of 873 (22.5%) new cases of chronic kidney disease occurred. Among them, participants diagnosed with sarcopenia (HR1.45; 95% CI 1.15-1.83) were more likely to develop new-onset chronic kidney disease than those without sarcopenia. Similarly, patients with sarcopenia were more likely to develop new-onset chronic kidney disease than those with possible sarcopenia (HR 1.27; 95%CI 1.00-1.60). Subgroup analysis revealed that elder adults aged between 60 and 75 years old (HR 1.666; 95%CI 1.20-22.28), with hypertension (HR 1.57; 95%CI 1.02-2.40), people with sarcopenia had a significantly higher risk of developing new-onset chronic kidney disease than those without sarcopenia (all P < 0.05).
CONCLUSION: Middle-aged and elder adults diagnosed with sarcopenia have a higher risk of developing new-onset chronic kidney disease.
The diagnosis, assessment of recurrence of inflammation, response to treatment and remission in EoE are all currently based on histological evaluation of upper endoscopic pinch esophageal biopsies. Obtaining biopsies for histological evaluation by this procedure is both invasive and expensive. The purpose of our longitudinal prospective study is to evaluate and quantify a panel of novel non-invasive eosinophilic inflammatory biomarkers in the blood and urine of subjects with EoE and compare their presence and levels with the presence or absence of measures of inflammation in esophageal biopsies. While evaluation of esophageal biopsies with 15 or more eosinophils per high power field is the gold standard for diagnosis of EoE, novel predictors of clinical outcome remain unclear. The objective is to identify one or more sensitive and specific non-invasive biomarkers that could be used to monitor esophageal inflammation, and identify novel tissue-based markers that identify phenotype and outcome. This would eliminate the need for invasive serial surveillance endoscopies for the purpose of evaluating for recurrence of inflammation or response to standard therapy since symptoms alone do not adequately correlate with either the presence or absence of disease activity (inflammation) in the esophagus of patients with EoE.
In the United States, labor inductions have increased from 11% of all pregnancies in 1989 to 21% in 2004. Although the indications for labor induction vary, labor inductions as an obstetrical practice are associated with an increased risk of Cesarean delivery. As such, the rise in labor inductions has been paralleled by a rise in the cesarean rate to an all time high of 30%. The risk of cesarean can be mitigated with the use of cervical ripening agents in the setting of an unfavorable cervix. Both pharmacological ripening agents and mechanical methods are currently available for cervical priming. Methods available for mechanical dilation include, but are not limited to transcervical foley catheter alone and transcervical foley catheter with an extra-amniotic saline infusion or EASI. The potential advantage of EASI to transcervical foley catheter alone is the promotion of endogenous prostaglandin release by membrane stripping and supplying additional mechanical force. It may be disadvantageous by increasing the risk of chorioamnionitis or by diluting the prostaglandins that are released by membrane stripping. There have been two randomized trials comparing foley alone to foley with EASI. Because the results of these two trials are conflicting, we chose to conduct a randomized clinical trial of foley catheter compared to foley catheter with an EASI for labor induction and cervical ripening in women with an unfavorable cervix.
This pilot study aims to examine feasibility of implementing a HRVB intervention and an MLC control with AD FCGs. The HRVB and MLC interventions will be evaluated for acceptability (operationalized as adherence to intervention) and satisfaction and to identify necessary intervention modifications. Feasibility benchmarks: 85% of participants will be at least 70% adherent to implementation goals (10-min use 5-7 days per week). Feasibility of randomization will be examined by comparing adherence/retention (expecting similar patterns across interventions). Acceptability/satisfaction with HRVB and MLC will be evaluated in semi-structured interviews post-intervention including detailed probing on feature preferences, barriers/facilitators, suggested improvements for retention.

The second aim of this study is to examine patterns of association of HRVB and MLC with outcomes. The investigators will examine pre- to post-intervention changes (and sustained outcomes at follow-up) in self-reported caregiver burden, stress and resilience. Change in relationship quality will additionally be assessed from pre- to post intervention. Change in ANS balance, a neurophysiological indicator of reduced emotional distress and improved resilience, will be assessed using HRV data at all four timepoints to examine trends and change over time. Significance tests will not be conducted, in alignment with goals for pilot feasibility studies. The investigators will observe the direction of change and outcomes to examine the value of MLC as an appropriate control condition showing minimal placebo effects compared to HRVB.
PCT No. PCT/DE94/00333 Sec. 371 Date Mar. 5, 1996 Sec. 102(e) Date Mar. 5, 1996 PCT Filed Mar. 23, 1994 PCT Pub. No. WO94/21273 PCT Pub. Date Sep. 29, 1994The invention proposes a way to generally prevent or at least severely limit the secretion of proteins, particularly the secretion of enzymes from leucocytes. By administering an agent containing one or more active ingredients selected from the group consisting of angiogenine,  alpha 1-microglobulin, complement factor D, fragments or peptides with the biologically effective sequential ranges of these peptides, and peptidomimetica to the source of secretion the secretion can be prevented or at least drastically limited.
The present invention relates to a convenience food for serving to treat and prevent prostatic diseases which is made from the following materials based on weight percent: pumpkin seed 20-50 percent, okra 10-15 percent, black sesame 10-20 percent, cassia bark 3-5 percent, angelica 20-30 percent and liquorice 3-6 percent. The convenience food for serving to cure and prevent prostatic diseases has simple manufacturing method, has little side-effect. After eating the convenience food for a long term, the symptom of patients can be improved obviously, and the pain can be released a lot. The convenience food also can be eaten directly as the food for the three meals. After being flavored, both the taste and the flavor can be easily accepted and accustomed by elderly patients. The present invention has low cost and low prevention and treatment cost, and is a better way of assistant treatment and prevention for the patients.
Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8-28 weeks after starting GnRH agonist, patients undergo IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
Several randomized control trials (RCTs) have been published comparing open (ORC) with robot-assisted radical cystectomy (RARC). However, uncertainty persists regarding this issue, as evidences and recommendations on RARC are still lacking. In this systematic review and metaanalysis, we summarized evidence in this context. A literature search was conducted according to PRISMA criteria, using PubMed/Medline, Web Of Science and Embase, up to March 2024. Only randomized controlled trials (RCTs) were selected. The primary endpoint was to investigate health-related quality of life (QoL) both at 3 and 6 months after surgery. Secondary endpoints include pathological and perioperative outcomes, postoperative complications and oncological outcomes. Furthermore, we conducted a cost evaluation based on the available evidence. Eight RCTs were included, encompassing 1024 patients (515 RARC versus 509 ORC). QoL appeared similar among the two groups both after 3 and 6 months. No significant differences in overall and major complications at 30 days (p = 0.11 and p > 0.9, respectively) and 90 days (p = 0.28 and p = 0.57, respectively) were observed, as well as in oncological, pathological and perioperative outcomes, excepting from operative time, which was longer in RARC (MD 92.34 min, 95% CI 83.83-100.84, p < 0.001) and transfusion rate, which was lower in RARC (OR 0.43, 95% CI 0.30-0.61, p < 0.001). Both ORC and RARC are viable options for bladder cancer, having comparable complication rates and oncological outcomes. RARC provides transfusion rate advantages, however, it has longer operative time and higher costs. QoL outcomes appear similar between the two groups, both after 3 and 6 months.
Isolated Left Ventricular Non-compaction (LVNC) is a type of cardiomyopathy that usually has a genetic origin. Its diagnosis is based on finding such as deep intertrabecular recesses or sinusoids and ventricular trabeculations communicating with the left ventricular cavity. LVNC was first clinically recognised almost four decades ago, yet its diagnostic and management challenges persist. In this report, we present the case of an 18-year-old boy, who presented at the National Institute of Cardiovascular Diseases, Karachi, in March 2023, with complaints of dizziness, pedal oedema, and shortness of breath. Echocardiography revealed signs suggestive of LVNC, which were confirmed conclusively on Cardiovascular Magnetic Resonance (CMR) (NC/C ratio>2.4). The patient underwent implantable cardioverter defibrillator (ICD) placement, was discharged after a smooth post-procedure recovery, and is doing well on follow-ups. Hence, ICD and guideline-directed medical therapy as a combination have turned out to have satisfactory outcomes in decreasing morbidity and providing mortality benefits for such patients.
<P>PROBLEM TO BE SOLVED: To obtain a photocurable composition which has excellent curability, has reduced surface unpolymerized amount due to slight polymerization inhibition with oxygen and is useful as a material for tooth crown restoration.  <P>SOLUTION: The photocurable composition for tooth crown restoration comprises a polymerizable monomer, a photopolymerization initiator and, if necessary, a polymerization inhibitor. The mixture of the polymerizable monomer, the photopolymerization initiator and the polymerization inhibitor has 900-4,000cP viscosity at 23°C. Preferably the photocurable composition is further mixed with an inorganic filler in terms of operability and mechanical strength of cured body useful as a material for tooth crown restoration. The addition of the inorganic filler remarkably changes (increases) viscosity and the viscosity range in 900-4,000cP is a value in an unmixed state of the inorganic filler.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Periostin, a multifunctional 90 kDa protein, plays a pivotal role in the pathogenesis of fibrosis across various tissues, including skeletal muscle. It operates within the transforming growth factor beta 1 (Tgf-β1) signalling pathway and is upregulated in fibrotic tissue. Alternative splicing of Periostin's C-terminal region leads to six protein-coding isoforms. This study aimed to elucidate the contribution of the isoforms containing the amino acids encoded by exon 17 (e17+ Periostin) to skeletal muscle fibrosis and investigate the therapeutic potential of manipulating exon 17 splicing. We identified distinct structural differences between e17+ Periostin isoforms, affecting their interaction with key fibrotic proteins, including Tgf-β1 and integrin alpha V. In vitro mouse fibroblast experimentation confirmed the TGF-β1-induced upregulation of e17+ Periostin mRNA, mitigated by an antisense approach that induces the skipping of exon 17 of the Postn gene. Subsequent in vivo studies in the D2.mdx mouse model of Duchenne muscular dystrophy (DMD) demonstrated that our antisense treatment effectively reduced e17+ Periostin mRNA expression, which coincided with reduced full-length Periostin protein expression and collagen accumulation. The grip strength of the treated mice was rescued to the wild-type level. These results suggest a pivotal role of e17+ Periostin isoforms in the fibrotic pathology of skeletal muscle and highlight the potential of targeted exon skipping strategies as a promising therapeutic approach for mitigating fibrosis-associated complications.